FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

The FDA in­di­cat­ed that it will main­tain some pan­dem­ic-era flex­i­bil­i­ties in in­sti­tu­tion­al re­view board (IRB) as­sess­ments of ex­pand­ed ac­cess drugs for in­di­vid­ual pa­tients in im­me­di­ate­ly-in-ef­fect guid­ance pub­lished Fri­day.

The FDA ex­plains in the eight-page guid­ance that ex­pand­ed ac­cess drugs refers to in­ves­ti­ga­tion­al drugs that serve the main pur­pose of treat­ing, di­ag­nos­ing or mon­i­tor­ing a pa­tient’s dis­ease as op­posed to glean­ing in­for­ma­tion about the drug, which is gen­er­al­ly the main pur­pose of a clin­i­cal tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER